A Low Frequency of Losses in 11q Chromosome Is Associated with Better Outcome and Lower Rate of Genomic Mutations in Patients with Chronic Lymphocytic Leukemia by Hernández, José Ángel et al.
RESEARCH ARTICLE
A Low Frequency of Losses in 11q
Chromosome Is Associated with Better
Outcome and Lower Rate of Genomic
Mutations in Patients with Chronic
Lymphocytic Leukemia
José Ángel Hernández1☯, María Hernández-Sánchez2☯, Ana Eugenia Rodríguez-Vicente2,
Vera Grossmann3, Rosa Collado4, Cecilia Heras1, Anna Puiggros5, Ana África Martín6,
Noemí Puig6, Rocío Benito2, Cristina Robledo2, Julio Delgado7, Teresa González8, José
Antonio Queizán9, Josefina Galende10, Ignacio de la Fuente11, GuillermoMartín-Núñez12,
JoséMaría Alonso13, Pau Abrisqueta14, Elisa Luño15, Isabel Marugán16, Isabel González-
Gascón1, Francesc Bosch14, Alexander Kohlmann3,17, MarcosGonzález2,6, Blanca Espinet5,
Jesús María Hernández-Rivas2,6,18*, Grupo Cooperativo Español de Citogenética
Hematológica (GCECGH) and Grupo Español de Leucemia Linfática Crónica (GELLC)¶
1 Hematology Department, Hospital Universitario Infanta Leonor, Universidad Complutense de Madrid,
Madrid, Spain, 2 IBSAL, IBMCC, Centro de Investigación del Cáncer, Universidad de Salamanca,CSIC,
Hospital Universitario de Salamanca, Spain, 3 MLL Munich, Germany, 4 Hematology Department, Hospital
General, Valencia, Spain, 5 Pathology Department, Hospital del Mar, Barcelona, Spain, 6 Hematology
Department, Hospital Universitario, Salamanca, Spain, 7 Hematology Department, Hospital Clinic i
Provincial, Barcelona, Spain, 8 Fundación Pública Galega de Medicina Xenómica, Santiago de Compostela,
Spain, 9 Hematology Department, Hospital General, Segovia, Spain, 10 Hematology Department, Hospital
del Bierzo, Ponferrada, León, Spain, 11 Hematology Department, Hospital Universitario Río Hortega,
Valladolid, Spain, 12 Hematology Department, Hospital Virgen del Puerto, Plasencia, Cáceres, Spain,
13 Hematology Department, Hospital Río Carrión, Palencia, Spain, 14 Hematology Department, Hospital
Vall d'Hebron, Barcelona, Spain, 15 Hematology Department, Hospital Central de Asturias, Oviedo, Spain,
16 Hematology Department, Hospital Clínico, Valencia, Spain, 17 AstraZeneca, Personalized Healthcare
and Biomarkers, Innovative Medicines, Macclesfield, United Kingdom, 18 Department of Medicine,
Universidad de Salamanca, Spain
☯ These authors contributed equally to this work.
¶ Membership of the DataBase of CLL of Grupo Cooperativo Español de Citogenética Hematológica
(GCECGH) and Grupo Español de Leucemia Linfocítica Crónica (GELLC) is provided in the
Acknowledgments.
* jmhr@usal.es
Abstract
To analyze the impact of the 11q deleted (11q-) cells in CLL patients on the time to first ther-
apy (TFT) and overall survival (OS), 2,493 patients with CLL were studied. 242 patients
(9.7%) had 11q-. Fluorescence in situ hybridization (FISH) studies showed a threshold of
40% of deleted cells to be optimal for showing that clinical differences in terms of TFT and
OS within 11q- CLLs. In patients with40% of losses in 11q (11q-H) (74%), the median
TFT was 19 months compared with 44 months in CLL patients with <40% del(11q) (11q-L)
(P<0.0001). In the multivariate analysis, only the presence of 11q-L, mutated IGHV status,
early Binet stage and absence of extended lymphadenopathy were associated with longer
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TFT. Patients with 11q-H had an OS of 90 months, while in the 11q-L group the OS was not
reached (P = 0.008). The absence of splenomegaly (P = 0.02), low LDH (P = 0.018) or β2M
(P = 0.006), and the presence of 11q-L (P = 0.003) were associated with a longer OS. In
addition, to detect the presence of mutations in the ATM, TP53, NOTCH1, SF3B1,MYD88,
FBXW7, XPO1 and BIRC3 genes, a select cohort of CLL patients with losses in 11q was
sequenced by next-generation sequencing of amplicons. Eighty % of CLLs with 11q-
showed mutations and fewer patients with low frequencies of 11q- had mutations among
genes examined (50% vs 94.1%, P = 0.023). In summary, CLL patients with <40% of 11q-
had a long TFT and OS that could be associated with the presence of fewer mutated genes.
Introduction
In chronic lymphocytic leukemia (CLL) the presence of cytogenetic aberrations assessed by
fluorescence in situ hybridization (FISH) influences the prognosis, in terms of time to first
therapy (TFT), response to treatment, and overall survival (OS) [1]. Deletions on 11q are
observed in 9–18% of CLL patients [1,2]. These patients are younger, have abdominal bulky
lymph node involvement [3,4], and often show ZAP-70 expression, unmutated status of IGHV
and shorter survival, although with a highly variable clinical outcome. The use of chemoimmu-
notherapy, including rituximab and cyclophosphamide to fludarabine schedules, can improve
the response in patients with 11q deletion [5].
Deletions of 11q almost invariably include the ataxia telangiectasia mutated (ATM) gene
[6]. This important tumor suppressor gene plays a crucial role in DNA repair and recombina-
tion, and regulates cell cycle progression [7]. Although mutations of this gene have been linked
to poor prognosis and are associated with 11q deletions in CLL patients, due to its extreme size
(62 coding exons) with lack of well characterized (hot-spot) mutations, ATM sequencing stud-
ies in CLL have been challenging, leaving several issues unresolved [8–10].
The application of next-generation sequencing (NGS) allows the detection of new candidate
genes with frequent mutations in CLL patients as detected by whole-exome and whole-genome
sequencing [11–14]. Besides TP53mutations [15,16], NOTCH1 and SF3B1, found in around
10% of newly diagnosed CLL patients, are the most frequently mutated genes [17,18]. Patients
with mutations in some of these genes have been associated with shorter TFT and OS [19,20].
Other recurrent mutations inMYD88, FBXW7, XPO1 and BIRC3 genes have been reported at
frequencies below 10% [19,21]. Moreover, BIRC3, a negative regulator of NFKB signaling path-
way, is located near to ATM gene, at 11q22 [9].
In the last few years, it has been reported that patients with CLL and 13q deletion may differ
in their outcomes depending on the percentage of cells displaying this aberration [2,22–24]. To
assess the potential prognostic value of the number of cells with deletion on 11q and to gain
insight into the molecular basis of this abnormality in CLL, we have performed a multicenter
study of a large series of patients diagnosed with 11q- CLL to determine whether the frequency
of losses in 11q has an influence on OS and TFT. Furthermore, NGS studies were carried out,
in a subset of patients, to analyze the mutational status of ATM, TP53, NOTCH1, SF3B1,
MYD88, FBXW7, XPO1 and BIRC3 in this group of patients.
Methods
Patients
A total of 2,493 patients registered in the DataBase of CLL of the Spanish Group of Cytogenet-
ics (GCECGH) and the Spanish Group of CLL (GELLC) were included. The diagnosis of CLL
11 Deletion Associated with Better Outcome and Lower Mutations in CLL
PLOSONE | DOI:10.1371/journal.pone.0143073 December 2, 2015 2 / 16
Banca Cívica (Caja Burgos), Fundación Española de
Hematología y Hemoterapia (FEHH), and by grants
(RD12/0036/0069 and RD12/0036/0044) from Red
Temática de Investigación Cooperativa en Cáncer
(RTICC), Instituto de Salud Carlos III (ISCIII),
Spanish Ministry of Economy and Competitiveness
and European Regional Development Fund (ERDF)
"Una manera de hacer Europa" (CEI 2010-1-0010).
The research leading to these results has received
funding from the European Union Seventh
Framework Programme [FP7/2007-2013] under
Grant Agreement n°306242-NGS-PTL. Mutation
analyses were performed using oligonucleotide
primer plates designed as part of the IRON-II
collaborative network of hematological laboratories
applying 454 amplicon next-generation deep-
sequencing. The funders had no role in study design,
data collection and analysis, decision to publish, or
preparation of the manuscript. María Hernández-
Sánchez is fully supported by an Ayuda Predoctoral
de la Junta de Castilla y León from the Fondo Social
Europeo (JCYL-EDU/346/2013 Ph.D. scholarship).
Vera Grossmann was supported by MLL Munich and
Alexander Kohlmann was supported by MLL Munich
and AstraZeneca in terms of salary. These funders
provided support in the form of salaries for these
authors but did not have any additional role in the
study design, data collection and analysis, decision to
publish, or preparation of the manuscript. The specific
roles of these authors are articulated in the 'author
contributions' section.
Competing Interests: The authors have declared
that no competing interests exist. Oligonucleotide
primer plates for amplicon deep-sequencing were
provided by Roche Diagnostics, Penzberg, Germany,
as part of the IRON-II study. VG and AK were
employed by MLL Munich Leukemia Laboratory and
AK is employed by AstraZeneca. This does not alter
the authors' adherence to PLOS ONE policies on
sharing data and materials.
was made according to the International Workshop on CLL (IWCLL) criteria [25]. In all cases,
an immunophenotypic analysis was performed by flow cytometry. FISH studies, including spe-
cific probes for at least the 11q22.3–23.1, 12p11.1-q11, 13q14, and 17p13 regions were carried
out.
A total of 242 patients (9.7%) had an 11q deletion. The final analysis was limited to 197
cases, including 11q deletion performed at diagnosis of CLL, after excluding cases with mono-
clonal B-cell lymphocytosis, clonal evolution or inappropriate follow-up (Table A in S1 File).
Basic clinical and biological data were recorded by reviewing the GCECGH and GELLC Data-
Base. The study was approved by the local ethical committees “Comité Ético de Investigación
Clínica, Hospital Universitario de Salamanca”. Written informed consent was obtained from
each patient before they entered the study.
Fluorescence in situ hybridization (FISH)
Interphase FISH was performed in peripheral blood samples using commercially available
probes for the 13q14, 12p11.1-q11 (alpha satellite), 11q22/ATM and 17p13/P53 regions (Vysis/
Abbott Co, Abbott Park, IL, USA). Dual-color FISH using differently labeled control probes
and test probes were performed. The methods used for FISH analysis have been described else-
where [26]. Signal screening was carried out in at least 200 cells with well-delineated fluores-
cent spots. In cases with 11q deletion a score of10% was considered positive, according to
the cut-off of our laboratories.
Next-generation sequencing analysis
A total of 25 11q- CLL patients were included in sequencing studies. Samples were obtained at
diagnosis in all cases. NGS was performed using 454 Titanium Amplicon chemistry (Roche
Applied Science, Penzberg, Germany) [27] to investigate the ATM, TP53, NOTCH1, SF3B1,
MYD88, FBXW7, XPO1 and BIRC3mutations in 11q- CLL patients. Information about primer
sequences is shown in Table E in S1 File and the PCR conditions are described in Table F in S1
File. The oligonucleotide design was performed as part of the IRON-II network.
All data were generated using the GS FLX and Junior Sequencer Instrument software ver-
sion 2.7 (Roche Applied Science). To detect variants, filters were set to display sequence vari-
ants occurring in more than 2% of bidirectional reads per amplicon in at least one patient.
Table G in S1 File shows the median number of reads generated for each gene, allowing vari-
ants to be identified down to a detection limit of 2% [28].
Detailed methods are described in the S1 File. The sequencing data are uploaded to the
Sequence Read Archive (SRA) (http://trace.ncbi.nlm.nih.gov/Traces/sra/) under accession
number PRJNA297249. All the information is accessible with the following link http://www.
ncbi.nlm.nih.gov/bioproject/297249.
Statistical analysis
Statistical analysis were performed using SPSS 20.0 for Windows (SPSS, Chicago, IL, USA).
TFT and OS were analyzed on the date of the initial FISH study, coinciding in all of cases with
CLL diagnosis. The number of losses in 11q-deleted nuclei was divided into deciles to better
define the most significant cut-off point for TFT and OS. The chi-square test was used to assess
associations between categorized variables, while continuous variables were analyzed with the
Mann-Whitney U test. Statistically significant variables related to TFT and OS were estimated
by the Kaplan-Meier method, using the log-rank test to compare the curves of each group. Uni-
variate and multivariate analyses of the TFT and OS employed the Cox regression method.
Results were considered statistically significant for values of P0.05.
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Results
Clinical and biological characteristics of CLL patients carrying 11q
deletion
One hundred ninety-seven patients with 11q deletion were selected for the analysis. There was a
predominance of males (76.6%), and the median age was 65 years (range: 28–97 years). Most
patients (61%) were in Binet stage A and only 14.9% had B symptoms. In 46.4% of patients the
lymphocyte blood count was20 x 109/L, while 31.8% and 28.9% patients, respectively, had high
serum β2-microglobulin and high serum LDH levels. A total of 68.5% of patients had lymph
node involvement, and splenomegaly was detected in 23.4% of cases. Regarding biological
characteristics, IGHV unmutated cases were present in 66.1% of cases, while CD3830% and
ZAP-7020% were detected in 55% and 55.7% of patients, respectively (Table A in S1 File).
Fifty-one patients (25.9%) had<40% of 11q-deleted cells, while 146 cases (74.1%)
had40% of such cells. Different cut-off points were analysed, and 40% 11q deleted nuclei was
selected to better separate patients with different disease outcome. In 82 out of 197 patients
(41.6%) 11q- was the sole cytogenetic aberration, while 115 patients (58.4%) had 11q deletion
plus other cytogenetic abnormalities (108 cases had a 13q deletion, 14 had trisomy 12, and 6
patients showed a 17p deletion).
No significant differences in clinical or biological features were found between patients with
low (<40%) and high (40%) frequencies of 11q- cells, except for the number of lymphocytes,
Binet stage, IGHVmutational status, need for therapy, and death during follow-up (Table 1).
CLL patients with a low number of 11q- cells have a prolonged time to
first therapy (TFT)
All 197 patients were evaluable for analysis of TFT, response to therapy and OS. By the time of
analysis, 151/197 (76.6%) had received treatment, with a median TFT of 25 months (95% CI,
31–44 months) (Fig A in S1 File.). In terms of TFT, no differences in the group of 11q deletion
as unique FISH cytogenetic aberration compared with the group of 11q deletion plus other
FISH alterations were observed. A significantly longer TFT was detected in the cohort of
patients with<40% of 11q deleted cells (median, 44 months; 95% CI, 33–55 months) vs those
patients40% losses in 11q (median, 19 months; 95% CI, 12–24 months) (P<0.0001) (. 1A).
Of note, 52% of patients in the former group required treatment while 70.5% of patients
with40% of 11q-deleted nuclei were treated. Variables associated with a longer TFT were
early clinical stage (P = 0.024), absence of extended lymphadenopathy (<2 node areas
involved) (P<0.0001), absence of splenomegaly (P = 0.045), low serum LDH (P = 0.045), low
serum β2M (P = 0.019), low CD38 expression (P = 0.023), low ZAP70 expression (P = 0.025),
mutated IGHV status (P<0.0001) and del(11q) in<40% of cells (P<0.0001) (Table B in S1
File). In the multivariate analysis, only the presence of del(11q) in<40% of cells (Hazard
Ratio, HR, 4.475; 95% CI, 1.813–7.171; P = 0.001), mutated IGHV status (HR, 3.659;
P = 0.005), early Binet stage (HR 2.492; P = 0.023) and absence of extended lymphadenopathy
(HR 1.854; P = 0.016) identified independent risk factors associated with longer TFT (Table 2).
In addition, in patients with del(11q) as the sole cytogenetic aberration, a longer TFT was
observed in patients with 11q-L (median 45 months vs 15 months, P< 0.0001).
CLL patients with a low number of 11q- cells have longer overall survival
(OS)
By the time of analysis, 60/197 patients (30.5%) had died. The median OS of the global series
was 106 months (95% CI, 97–128 months) (Fig A in S1 File). Significantly longer survival was
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Table 1. Characteristics of 197 patients with 11q deletion with respect to the number of losses detected by FISH: <40% (n = 51) or40% (n = 146).
Characteristic Category del(11q) <40%, del(11q) 40%, P
N = 51 (26%) N = 146 (74%)
Age, years 62 (28–84) 65 (33–91) 0.13
White blood cells, range /μL 17,900 (7,800–98,100) 28,000 (6,600–365,000) 0.008
Lymphocytes, range /μL 12,600 (5,100–84,8500) 21,100 (5,200–364,000) 0.007
Lymphocytes > 20 x 109/L
Yes 14 75 0.005
No 35 68
Hemoglobin, range g/dL 14 (6–17) 14 (5–17) 0.91
Platelet count, range /μL 195,000 (63,000–352,000) 182,000 (2,000–412,000) 0.44
IGHV (n = 56)*
Mutated 9 10 0.024
Unmutated 6 31
ZAP-70 (n = 79)*
+ 12 32 0.44
- 11 24
CD38 (n = 130)*
+ 16 40 0.139
- 19 56
del(11q) as sole cytogenetic aberration
Yes 20 62 0.74
No 31 84
del(11q) + del(13q)
Yes 29 77 0.63
No 22 69
Sex
Male 40 111 0.84
Female 11 35
LDH (n = 187)*
Normal 34 99 0.49
High 13 41
β microglobulin (n = 170) *
Normal 33 80 0.19
High 11 43
Binet stage (n = 195)*
A 36 83 0.17
B 10 44
C 4 14
Lymphadenopathy (n = 193)*
No 20 41 0.12
 2 nodal areas 16 43
> 2 nodal areas 13 60
Hepatomegaly (n = 193)*
Yes 3 15 0.57
No 46 129
Splenomegaly (n = 193)*
Yes 10 36 0.43
No 39 108
B symptoms (n = 195)*
(Continued)
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observed in patients with a low frequency of losses in 11q-. Thus, in patients with loss of 11q in
40% of cells, the OS was 90 months (95% CI, 57–123 months), while in the group with<40%
of losses in 11q, the median OS had not been reached (95% CI, 114–157 months) (P = 0.006)
(Fig 1B). In the univariate analysis, early clinical Binet stage (P = 0.001), asymptomatic disease
(P = 0.034), absence of hepatomegaly (P = 0.025) or splenomegaly (P<0.0001), lymphocyte
count<20 x 109/L (P = 0.032), low serum of either LDH level (P<0.0001) or β2M (P<0.0001),
the presence of an association of 11q deletion and 13q deletion (P = 0.045), and a low number
(<40%) of cells with 11q- (P = 0.006) were associated with longer OS (Table C in S1 File). In
the multivariate analysis, the variables independently related to longer OS were the absence of
splenomegaly (HR, 1.786; P = 0.023), low serum LDH (HR, 2.076; P = 0.018), low serum β2M
(HR, 2.448; P = 0.006) and the presence of del(11q) in<40% of cells (HR, 3.145; 95% CI,
1.474–6.691; P = 0.003) (Table 3).
Regarding the patients with del(11q) as the unique cytogenetic aberration, a longer OS was
observed in patients with 11q-L (median not reached vs 70 months, P = 0.007)
The analyses of other cut-offs for the number of 11q- cells (<40% vs 40–59% vs60%)
showed similar results for TFT and OS (Fig B in S1 File).
Table 1. (Continued)
Characteristic Category del(11q) <40%, del(11q) 40%, P
N = 51 (26%) N = 146 (74%)
Yes 6 23 0.34
No 44 122
Second Cancer (n = 172)*
Yes 4 22 0.23
No 42 104
Died during follow-up
Yes 10 50 0.04
No 41 96
Therapy during follow-up
Yes 27 104 0.025
No 24 42
*Number of cases.
doi:10.1371/journal.pone.0143073.t001
Table 2. Multivariate Cox regression analysis of time to first therapy in 11q- CLL patients with respect to the number of losses detected by FISH:
<40% (n = 51) or40% (n = 146).*
Variable Hazard Ratio 95% CI P (log-rank test)
del(11q) <40% 4.475 1.813–7.171 0.001
Mutated IGHV 3.659 1.478–9.057 0.005
Early Binet stage 2.492 1.137–5.463 0.023
Non-extended lymphadenopathy ( 2 nodal areas) 1.854 1.121–3.065 0.016
*The following covariates were included in the ﬁnal model: age, sex, Binet stage, splenomegaly, extended lymphadenopathies, LDH, β2 microglobulin,
CD38, ZAP70, IGHV mutation status and percentage 11q deleted nuclei.
doi:10.1371/journal.pone.0143073.t002
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Biallelic inactivation of the ATM gene is observed in one-third of 11q-
CLL patients
ATMmutations were found in eight (32%) of 25 patients with 11q-. In total, 14 different muta-
tions were detected by ATMmolecular mutation screening: 11 point mutations (7 missense
and 4 nonsense; 78.6%) and three frameshift mutations (2 deletions and 1 insertion; 21.4%).
These mutations are shown in Fig 2 and listed in Table 4. All patients with mutated ATM had
at least one truncating or damaging mutation. Interestingly, four of the eight patients with
ATMmutations carried more than one type of mutation. Thus, two patients with ATMmuta-
tions carried two different mutations while two other patients with ATMmutations carried
three mutations. It is of note that the patients with several ATMmutations had different muta-
tional loads, suggesting the presence of independent clones or clonal evolution with the
Fig 1. (A) Time to first therapy (TFT) and (B) overall survival (OS) of 197 patients with 11q deletion CLL and <40% or40% FISH losses.
doi:10.1371/journal.pone.0143073.g001
Table 3. Multivariate Cox regression analysis of overall survival in 11q- CLL patients with respect to
the number of losses detected by FISH: <40% (n = 51) or40% (n = 146).*
Variable Hazard Ratio 95% CI P (log-rank test)
Del 11q <40% 3.145 1.474–6.691 0.003
Low serum β2 microglobulin 2.448 1.260–4.753 0.006
Low serum LDH 2.076 1.061–4.064 0.018
Absence of splenomegaly 1.786 1.044–4.481 0.023
*The following covariates were included in the ﬁnal model: age, sex, Binet stage, splenomegaly, extended
lymphadenopathies, LDH, β2 microglobulin, CD38, ZAP70, IGHV mutation status and percentage 11q
deleted nuclei.
doi:10.1371/journal.pone.0143073.t003
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acquisition of a second mutation. However, it could not be confirmed whether the mutations
from one patient belonged to different clones, since they were located on distinct sequencing
reads in different amplicons.
All the mutations were located in exons 3–60, between amino acids 29 and 2913, and
involved the FAT and PI3K domains of the ATM protein. Five mutations resulted in a trun-
cated form of the ATM protein (termed ‘truncating’) while the remaining mutations resulted
in the expression of the full-length, but mutated form of the ATM protein (termed ‘non-trun-
cating’). These missense mutations were analyzed with SIFT algorithms, which predicted six of
them to be damaging. The median mutational burden was 14.3% (range, 2.0–92.5%). Eight of
14 (57.1%) variants had a mutational load of15% and thus would not have been detected by
capillary Sanger sequencing.
Fig 2. Localization and frequencies of mutations in ATM, SF3B1,NOTCH1, TP53, XPO1 and BIRC3 genes.Mutations are indicated at the amino-acid
level; each detected alteration is represented by a dot. Mutation type is represented by a dark (missense), white (nonsense) or grey (frameshift) dot. The
sequenced exons for each gene are represented with a grey line below each schematic protein organization.
doi:10.1371/journal.pone.0143073.g002
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The TFT and OS were assessed in all patients and related to the mutational status of the
ATM gene. There was no difference in TFT or OS between 11q- patients with and without
ATMmutations (P<0.970 and P<0.623, respectively). Interestingly, bivariate analyses indi-
cated that the presence of ATMmutations was a useful characteristic for identifying CLL
patients with a different TFT in the subgroup of CLL patients with low frequencies of 11q-.
Thus, CLL with ATMmutations had a shorter TFT than patients without ATMmutations (36
vs 46 months; P = 0.046). By contrast, 11q patients harboring40% of 11q- had shorter TFT
independently of ATMmutational status. Moreover, there was no significant association
between the presence of an ATMmutation and other clinical or biological prognostic factors
(Table D in S1 File).
SF3B1 is a frequently mutated gene in CLL patients with 11q-
Mutations in TP53, NOTCH1, SF3B1,MYD88, FBXW7, XPO1 and BIRC3 were analyzed in the
entire cohort of 25 CLL patients. In total, 20 mutations were detected: eight patients had SF3B1
mutations, five cases had mutations in NOTCH1, four in TP53, two in XPO1, while one CLL
had a mutation in BIRC3. Most of them had previously been described as mutations in the
COSMIC database. The median mutational burden was 27% (range, 3–81%). In 7/20 (35%)
variants the mutation load was15%. The frequency of 11q- CLL with associated mutations
Table 4. ATMmutations in 25 CLL patients with del(11q).
Patient
ID
FISH ATM mutations
%
11q-
11q-
Group
Other
abnormalities
Mutational
load (%)
Sequence
change
Exon Protein change Domain
protein
Type of
mutation
Consequence
(SIFT)
Reported
previously
14 27 11q-L 30% 13q- 13 c.85A>T 3 p.Lys29X - nonsense T -
14 27 11q-L 30% 13q- 24 c.6452G>C 44 p.Arg2151Thr FAT missense NT (Tolerated) -
2 33 11q-L - 56.5 c.7325A>C 50 p.Gln2442Pro FAT missense NT (Damaging) 1, 2, 3, 4
3 38 11q-L 89% 13q- 5.5 c.3024insT 20 p.Gln1009fs - frameshift T -
3 38 11q-L 89% 13q- 14.5 c.7072C>T 48 p.Gln2358X FAT nonsense T -
18 70 11q-H 37.5% 13q- 7 c.1304T>A 10 p.Leu435X - nonsense T -
18 70 11q-H 37.5% 13q- 2 c.4564G>C 30 p.Gly1522Arg - missense NT (Damaging) -
18 70 11q-H 37.5% 13q- 26 c.7328G>A 50 p.Arg2443Gln FAT missense NT (Damaging) 5, 6
6 73 11q-H - 43 c.3185delA 22 p.Asn1062fs - frameshift T -
6 73 11q-H - 7 c.8196C>A 56 p.Phe2732Leu PI3K missense NT (Damaging) -
6 73 11q-H - 3.5 c.8738A>G 60 p.Asp2913Gly PI3K missense NT (Damaging) -
23 82.5 11q-H - 14 c.1067delT 9 p.
Phe357LeufsX33
- frameshift T -
16 83 11q-H 56% 13q- 92.5 c.8175T>A 56 p.Asp2725Glu PI3K missense NT (Damaging) -
15 88.5 11q-H 85% 13q- 79.5 c.4609C>T 30 p.Gln1537X - nonsense T -
11q-L: 11q- with <40% 11q-
11q-H: 40% 11q-
T: Truncating mutation
NT: Non-truncating mutation
1 Fujimoto A et al Nature Genetics 2012
2 Ding et al Nature 2008
3 Davies H et al Cancer Research 2005
4 Vorechovsky Nature Genetics 1997
5 Yip S et al. J Pathol 2012
6 Greiner TC et al Proc Natl Acad Sci USA 2006.
doi:10.1371/journal.pone.0143073.t004
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was 8/25 (32%) for SF3B1, 5/25 (20%) for NOTCH1, 4/25 (16%) for TP53, 2/25 (8%) for
XPO1 and 1/25 (4%) for BIRC3. These mutations are shown in Fig 2 and listed in Table 5. Con-
firming previously published sequencing data, the most frequent SF3B1mutation was p.
Lys700Glu (4/8, 50%) while the presence of p.Pro2514Argfs4 was the most frequent NOTCH1
mutation (5/5, 100%). In addition, 50% of the 11q- CLL patients with TP53mutations also
showed 17p-.
In terms of prognostic relevance, significant differences were observed only in TFT between
11q- patients with and without NOTCH1mutations (5 vs 36 months; P = 0.031) and in OS
between patients with and without TP53mutations (1 vs 197 months; P<0.003) (Fig C in
S1 File).
Genetic mutations are associated with a higher percentage of 11q- cells
As a next step towards understanding the clinical differences within the 11q- subgroup, the
association between the presence of genetic mutations and the percentage of 11q- cells in CLL
patients was examined. The incidence of ATMmutations was similar in the two groups. Thus,
29.4% of patients with a high frequency of 11q- exhibited ATMmutations while 37.5% of
patients with a low frequency of 11q losses had ATMmutations (P = 0.513). However, consid-
ering the mutations of all the genes analyzed, fewer patients with low frequencies of 11q- had
mutations among genes examined compared with the subgroup of a high number of losses
Table 5. Mutations in other genes in 25 CLL patients with del(11q).
Patient
ID
FISH Mutations
%
11q-
11q-
group
Other
abnormalities
Gene Mutational load
(%)
Sequence
change
Exon Protein change COSMIC
database
10 26 11q-L - SF3B1 17 c.2225G>A 16 p.Gly742Asp COSM145923
14 27 11q-L 30% 13q- NOTCH1 6 c.7541_7542delCT 34 p.
Pro2514ArgfsX4
COSM12774
22 48 11q-H - SF3B1 4 c.2098A>G 15 p.Lys700Glu COSM84677
22 48 11q-H - TP53 28 c.824G>A 8 p.Cys275Tyr COSM10893
21 48.5 11q-H 81.5% 13q- SF3B1 25 c.1645C>T 12 p.Arg549Cys COSM1014502
21 48.5 11q-H 81.5% 13q- TP53 16 c.1024C>T 10 p.Arg342X COSM11073
25 62 11q-H - NOTCH1 68.5 c.7541_7542delCT 34 p.
Pro2514ArgfsX4
COSM12774
18 70 11q-H 37.5% 13q- SF3B1 34 c.2098A>G 15 p.Lys700Glu COSM84677
6 73 11q-H - SF3B1 39 c.2098A>G 15 p.Lys700Glu COSM84677
6 73 11q-H - NOTCH1 4 c.7541_7542delCT 34 p.
Pro2514ArgfsX4
COSM12774
20 78 11q-H 63% 13q- SF3B1 46.5 c.1988C>T 14 p.Thr663Ile COSM145921
16 83 11q-H 56% 13q- SF3B1 4 c.2098A>G 15 p.Lys700Glu COSM84677
13 83 11q-H 86% 13q- TP53 7.5 c.613T>G 6 p.Tyr205Asp COSM43844
9 83.5 11q-H 61% 13q- NOTCH1 3 c.7541_7542delCT 34 p.
Pro2514ArgfsX4
COSM12774
5 84.5 11q-H 87% 17p- NOTCH1 45 c.7541_7542delCT 34 p.
Pro2514ArgfsX4
COSM12774
19 84.5 11q-H 85% 13q- XPO1 47.5 c.1711G>A 15 p.Glu571Lys COSM96797
4 89 11q-H 87% 17p- TP53 81 c.833C>G 8 p.Pro278Arg COSM10887
4 89 11q-H 87% 17p- BIRC3 12 c.1813T>C 9 p.X605ArgextX11 -
1 90 11q-H 87%13q- SF3B1 50.5 c.1986C>G 14 p.His662Gln COSM110692
17 97 11q-H 97% 13q- XPO1 51 c.1712A>C 15 p.Glu571Ala COSM1291526
doi:10.1371/journal.pone.0143073.t005
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11q- (4/8, 50% vs 16/17, 94.1%; P = 0.023) (Fig 3). Interestingly, among the CLL patients with-
out a gene mutation, the median proportion of the CLL tumor population with an 11q deletion
was significantly lower than that of CLL patients with mutated genes (20.5%, range, 12–71.5%
vs 80.3%, range, 26–97%; P = 0.007). TP53mutations were present only in patients with a high
frequency of 11q- cells.
Discussion
In this study, we analyzed the outcome of 11q-deleted CLL patients at diagnosis with respect to
TFT and OS, and the presence of mutations in the most relevant genes to date in CLL. The
importance of the percentage of cells displaying a genetic aberration determined by FISH, as an
independent prognostic factor in CLL, has recently been recognized in 17p-, 13q- and +12
[2,22–24,29,30], whereby a high number of cells with 13q deletion has been associated with a
worse outcome [2,22–24]. In fact, patients displaying a high degree of infiltration of 13q- had
an intermediate prognosis, with a shorter time to first therapy and survival than those with
normal cytogenetics or trisomy 12 [2,22–24]. In addition, patients with fewer losses in 17p or
patients with a low number of trisomy 12 have a better outcome [29,31]. Several reports have
shown the 11q deletion to be a factor predicting poor prognosis in CLL [1,25,32]. In the present
study, we have confirmed these previous observations, whereby CLL patients with 11q- had a
median time of 2 years to receipt of first therapy and an overall survival of 8 years. Although
the present study is a retrospective and multicenter analysis of a series of CLLs, the characteris-
tics of the patients agree real-world basis. Thus, a median age of 65 years, predominance of
male sex (76%) and frequent lymphadenopathy (69%) were observed, as previously described
Fig 3. Distribution of mutations of ATM, SF3B1,NOTCH1, TP53, XPO1 and BIRC3 among 11q- CLL patients with respect to the percentage of 11q-
cells. In the heat maps, rows correspond to identical genes, and columns represent individual patients color-coded on the basis of gene status (white: wild
type; grey: mutated gene).
doi:10.1371/journal.pone.0143073.g003
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[1]. In addition, 66% of patients had unmutated IGHV status with more than 50% of cases
expressing CD38 and/or ZAP-70. Of note, we have observed that the number of cells carrying
11q- influences the disease outcome in terms of time to first therapy and overall survival. These
results are consistent with those of two recently published series that reported a longer TFT in
patients with 11q deletion and a low number of losses [33,34]. However, one of these studies
found no improvement in the overall survival in this group of patients [34]. Therefore, the
present study confirms that patients with 11q deletion do not comprise a homogeneous sub-
group. We identified a threshold of 40% of deleted cells to be optimal for showing that a low
number of losses in 11q is associated with a better outcome in terms of TFT and OS. However,
the use of other cut-off points (i.e.,<40% vs 40–59% vs60%) yielded similar results.
Interestingly, this study showed that CLL with losses in 11q with early clinical stage,
mutated IGHV status and/or a low number of losses in the 11q chromosome had a TFT of
more than two years compared with cases with>40% of cells with 11q deletion (median, 44 vs
19 months), similar to previously reported results [34]. Therefore, we identified the presence of
advanced clinical stages, unmutated IGHV, and a high number of losses in 11q as the main pre-
dictors indicating therapy in the group of CLL displaying 11q-.
Moreover, CLL patients with a lower percentage of 11q deletion had a better OS than those
with40% of 11q-deleted nuclei (median, not reached vs 90 months), with an estimated 3
years longer survival in patients with less than 40% of 11q deletions. In addition, clinical
(absence of splenomegaly) or biological variables (low 11q-, low LDH and β2M) were included
in the final multivariate model of OS. Therefore, the assessment of the number of 11q- cells
should be included to better define survival in patients with CLL displaying this genetic abnor-
mality and could be incorporated into the design of clinical trials to define their influence on
the response to new therapies and on survival.
To better define the molecular characteristics of the CLL patients displaying losses in 11q, a
mutational study performed by next-generation sequencing, including the most frequently
mutated genes in CLL, was carried out. The results showed that patients with a low number of
11q losses displayed fewer mutations. Interestingly, ATMmutations were present in both
cohorts of 11q- patients at a similar frequency to those previously reported [9,35–37]. We
found no significant impact of ATMmutations on prognosis for all the 11q- patients, as
described by other authors [9,37]. However, focusing on the group of patients with a low num-
ber of 11q losses, ATMmutations were useful for identifying CLL patients with a shorter TFT.
Thus, our results suggest that the integration of molecular markers, such as ATMmutations,
and the FISH analysis, in patients showing loss of 11q could provide a better prognostic stratifi-
cation than has been recently demonstrated in other CLL patients [20].
The presence of gene mutations has been widely demonstrated in CLL [11–14]. Mutations
of TP53, NOTCH1, SF3B1 and BIRC3 are known to be associated with a worse prognosis, while
mutations inMYD88 are related to a better outcome [18,19,21,38,39]. However, some of the
results concerning the incidence and independent prognostic value of these mutations are con-
troversial [12,14]. We observed a higher percentage of CLL patients with XPO1mutations in
our cohort of patients than in those described by others [12,13,19,40]. However, it should be
taken in account the limitation of the size of our sequencing samples cohort. Consistent with
previous studies, mutations of NOTCH1 and TP53 occurred as mutually exclusive events
[13,15]. Of note, TP53mutations were only detected in patients with a high frequency of
11q losses. Furthermore, NOTCH1 and SF3B1mutations were more frequent in this group of
11q- CLLs (Fig 3). Therefore, our study provides new insights into the molecular basis of the
worse outcome of CLL patients who have losses in 11q. It should be noted that the high fre-
quency of gene mutations did not involve the ATM gene, suggesting that the clonal evolution
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(heterogeneity) affecting any CLL-related gene could be the basis of the dismal prognosis of
patients with a high frequency of 11q- [12,40,41].
In summary, our results suggest that in patients with CLL, the frequency of 11q-deleted
cells influences the clinical outcome, and a low number of 11q- is associated with a longer time
to progression and overall survival. In addition, this study shows that fewer CLL patients with
low frequencies of 11q- had mutations among genes examined. Our findings, derived from a
large retrospective cohort of CLL patients from several Spanish institutions, need to be vali-
dated in prospective clinical trials.
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